Advances in influenza virus-like particles bioprocesses

References

• Gerdil C. The annual production cycle for influenza vaccine. Vaccine. 2003;21(16):1776–1779.
   PubMed Web of Science ®Google Scholar
• Kang S-M, Song J-M, Quan F-S, et al. Influenza vaccines based on virus-like particles. Virus Res. 2009;143(2):140–146.
   PubMed Web of Science ®Google Scholar
• Haynes JR. Influenza virus-like particle vaccines. Expert Rev Vaccines. 2012;7(4):435–445.
   Google Scholar
• Lee Y-T, Kim K-H, Ko E, et al. New vaccines against influenza virus. Clin Exp Vaccine Res. 2014;3(1):12.
   PubMedGoogle Scholar
• Quan F-S, Lee Y-T, Kim K-H, et al. Progress in developing virus-like particle influenza vaccines. Expert Rev Vaccines. 2016;15(10):1281–1293.
   PubMed Web of Science ®Google Scholar
• Landry N, Pillet S, Favre D, et al. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin Immunol. 2014;154(2):164–177.
   PubMed Web of Science ®Google Scholar
• Valero-Pacheco N, Pérez-Toledo M, Villasís-Keever MÁ, et al. Antibody persistence in adults two years after vaccination with an H1N1 2009 pandemic influenza virus-like particle vaccine. PLoS One. 2016;11(2):1–13.
   Web of Science ®Google Scholar
• López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine. 2011;29(44):7826–7834.
   PubMed Web of Science ®Google Scholar
• Pillet S, Aubin É, Trépanier S, et al. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin Immunol. 2016;168:72–87.
   PubMed Web of Science ®Google Scholar
• Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines. 2009;8(12):1681–1692.
   PubMed Web of Science ®Google Scholar
• Aucoin MG, Mena JA, Kamen AA. Bioprocessing of Baculovirus Vectors. Curr Gene Ther. 2010;10:174–186.
   PubMed Web of Science ®Google Scholar
• Vicente T, Roldão A, Peixoto C, et al. Large-scale production and purification of VLP-based vaccines. J Invertebr Pathol. 2011;107:S42–8.
   PubMed Web of Science ®Google Scholar
• Palmberger D, Wilson IBH, Berger I, et al. SweetBac: a new approach for the production of mammalianised glycoproteins in insect cells. PLoS One. 2012;7(4):e34226.
   PubMed Web of Science ®Google Scholar
• Wilde M, Klausberger M, Palmberger D, et al. Tnao38, high five and Sf9–evaluation of host-virus interactions in three different insect cell lines: baculovirus production and recombinant protein expression. Biotechnol Lett. 2014;36(4):743–749.
   PubMed Web of Science ®Google Scholar
• Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol. 2001;75(13):6154–6165.
   PubMed Web of Science ®Google Scholar
• Lua LHL, Connors NK, Sainsbury F, et al. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng. 2014;111(3):425–440.
   PubMed Web of Science ®Google Scholar
• Palmberger D, Klausberger M, Berger I, et al. MultiBac turns sweet. Bioengineered. 2013;4(2):78–83.
   PubMed Web of Science ®Google Scholar
• Hu Y-C, Yao K, Wu T-Y. Baculovirus as an expression and/or delivery vehicle for vaccine antigens. Expert Rev Vaccines. 2008;7(3):363–371.
   PubMed Web of Science ®Google Scholar
• Lin S-Y, Chung Y-C, Hu Y-C. Update on baculovirus as an expression and/or delivery vehicle for vaccine antigens. Expert Rev Vaccines. 2014;13(12):1501–1521.
   PubMed Web of Science ®Google Scholar
• Pushko P, Tumpey TM, Bu F, et al. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine. 2005;23(50):5751–5759.
   PubMed Web of Science ®Google Scholar
• Margine I, Martinez-Gil L, Chou -Y-Y, et al. Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PLoS One. 2012;7(12):e51559.
   PubMed Web of Science ®Google Scholar
• Monteiro F, Bernal V, Alves PM. The role of host cell physiology in the productivity of the baculovirus-insect cell system: fluxome analysis of Trichoplusia ni and Spodoptera frugiperda cell lines. Biotechnol Bioeng. 2016;114(3):674–684.
   PubMed Web of Science ®Google Scholar
• Krammer F, Schinko T, Palmberger D, et al. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol. 2010;45(3):226–234.
   PubMed Web of Science ®Google Scholar
• Klausberger M, Wilde M, Palmberger D, et al. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. Vaccine. 2014;32(3):355–362.
   PubMed Web of Science ®Google Scholar
• Fernandes F, Teixeira AP, Carinhas N, et al. Insect cells as a production platform of complex virus-like particles. Expert Rev Vaccines. 2013;12(2):225–236.
   PubMed Web of Science ®Google Scholar
• Bleckmann M, Schürig M, Chen FF, et al. Identification of essential genetic baculoviral elements for recombinant protein expression by transactivation in Sf21 insect cells. PLoS One. 2016;11(3):1–19.
   Web of Science ®Google Scholar
• Shen X, Hacker DL, Baldi L, et al. Virus-free transient protein production in Sf9 cells. J Biotechnol. 2013;171(1):61–70.
   PubMedGoogle Scholar
• Shen X, Pitol AK, Bachmann V, et al. A simple plasmid-based transient gene expression method using High Five cells. J Biotechnol. 2015;216:67–75.
   PubMed Web of Science ®Google Scholar
• Hong GP, Park JH, Lee HH, et al. Production of influenza virus-like particles from stably transfected Trichoplusia ni BT1 TN-5B1-4 cells. Biotechnol Bioprocess Eng. 2015;20(3):506–514.
   Web of Science ®Google Scholar
• Sequeira DP, Correia R, Carrondo MJT, et al. Combining stable insect cell lines with baculovirus-mediated expression for multi-HA influenza VLP production. Vaccine. 2017;9(October):107316.
   Google Scholar
• Lai JCC, Chan WWL, Kien FF, et al. Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase. J Gen Virol. 2010;91(Pt 9):2022–2030.
   Google Scholar
• Easterbrook JD, Schwartzman LM, Gao J, et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology. 2012;432(1):39–44.
   PubMed Web of Science ®Google Scholar
• Zhang L, Lu J, Chen Y, et al. Characterization of humoral responses induced by an H7N9 influenza virus-like particle vaccine in BALB/C Mice. Viruses. 2015;7(8):4369–4384.
   PubMed Web of Science ®Google Scholar
• Szécsi J, Gabriel G, Edfeldt G, et al. DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus. J Infect Dis. 2009;200(2):181–190.
   PubMed Web of Science ®Google Scholar
• Chlanda P, Schraidt O, Kummer S, et al. Structural analysis of the roles of influenza A virus membrane-associated proteins in assembly and morphology. J Virol. 2015;89(June):JVI.00592–15.
   PubMedGoogle Scholar
• Chen BJ, Leser GP, Morita E, et al. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol. 2007;81(13):7111–7123.
   PubMed Web of Science ®Google Scholar
• Yang J-R, Chen C-Y, Kuo C-Y, et al. A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses. Antiviral Res. 2016;126:8–17.
   PubMed Web of Science ®Google Scholar
• Tang X-C, Lu H-R, Ross TM. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge. Viral Immunol. 2011;24(4):311–319.
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Yeh Y-C, Yang Y-C, et al. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One. 2010;5(3):e9784.
   PubMed Web of Science ®Google Scholar
• Schmeisser F, Adamo JE, Blumberg B, et al. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase. Vaccine. 2012;30(23):3413–3422.
   PubMed Web of Science ®Google Scholar
• Wang D, Harmon A, Jin J, et al. The lack of an inherent membrane targeting signal is responsible for the failure of the matrix (M1) protein of influenza A virus to bud into virus-like particles. J Virol. 2010;84(9):4673–4681.
   PubMed Web of Science ®Google Scholar
• Le Ru A, Jacob D, Transfiguracion J, et al. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine. 2010;28(21):3661–3671.
   PubMed Web of Science ®Google Scholar
• Venereo-Sanchez A, Gilbert R, Simoneau M, et al. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: an effective influenza vaccine candidate. Vaccine. 2016;34(29):3371–3380.
   PubMed Web of Science ®Google Scholar
• Thompson CM, Petiot E, Mullick A, et al. Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems. BMC Biotechnol. 2015;15(1):31.
   PubMedGoogle Scholar
• Szécsi J, Boson B, Johnsson P, et al. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J. 2006;3:70.
   PubMed Web of Science ®Google Scholar
• Tom R, Bisson L, Durocher Y. Transfection of HEK293-EBNA1 cells in suspension with linear PEI for production of recombinant proteins. Cold Spring Harb Protoc. 2008;3(3):1–5.
   Google Scholar
• Ansorge S, Lanthier S, Transfiguracion J, et al. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures. J Gene Med. 2009;11(10):868–876.
   PubMed Web of Science ®Google Scholar
• Hsu CS, Ho YC, Wang KC, et al. Investigation of optimal transduction conditions for baculovirus-mediated gene delivery into mammalian cells. Biotechnol Bioeng. 2004;88(1):42–51.
   PubMed Web of Science ®Google Scholar
• Krammer F, Grabherr R. Alternative influenza vaccines made by insect cells. Trends Mol Med. 2010;16(7):313–320.
   PubMed Web of Science ®Google Scholar
• Chen CY, Lin CY, Chen GY, et al. Baculovirus as a gene delivery vector: recent understandings of molecular alterations in transduced cells and latest applications. Biotechnol Adv. 2011;29(6):618–631.
   PubMed Web of Science ®Google Scholar
• Kanagarajan S, Tolf C, Lundgren A, et al. Transient expression of hemagglutinin antigen from low pathogenic avian influenza A (H7N7) in Nicotiana benthamiana. PLoS One. 2012;7(3):e33010.
   PubMed Web of Science ®Google Scholar
• Saxena P, Lomonossoff G. Production of virus-like particles in plants. In: Viral Nanotechnol. CRC Press. 2015;251–262.
   Google Scholar
• D’Aoust M-A, Lavoie P-O, Couture MM-J, et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J. 2008;6(9):930–940.
   PubMed Web of Science ®Google Scholar
• D’Aoust M-A, Couture MM-J, Charland N, et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J. 2010;8(5):607–619.
   PubMed Web of Science ®Google Scholar
• Nayak DP, Balogun RA, Yamada H, et al. Influenza virus morphogenesis and budding. Virus Res. 2009;143(2):147–161.
   PubMed Web of Science ®Google Scholar
• Rossman JS, Lamb RA. Influenza virus assembly and budding. Virology. 2011;411(2):229–236.
   PubMed Web of Science ®Google Scholar
• Sokolenko S, George S, Wagner A, et al. Co-expression vs. co-infection using baculovirus expression vectors in insect cell culture: benefits and drawbacks. Biotechnol Adv. 2012;30(3):766–781.
   PubMed Web of Science ®Google Scholar
• Eibl R, Steiger N, Wellnitz S, et al. Fast single-use VLP vaccine productions based on insect cells and the baculovirus expression vector system: influenza as case study. In: Eibl R. (eds) Disposable Bioreactors II. Advances in Biochemical Engineering/Biotechnology, vol 138. Springer, Berlin, Heidelberg; 2013. p. 99–125.
   Google Scholar
• Choi JG, Kim MC, Kang HM, et al. Protective efficacy of baculovirus-derived influenza virus-like particles bearing H5 HA alone or in combination with M1 in chickens. Vet Microbiol. 2013;162(2–4):623–630.
   PubMed Web of Science ®Google Scholar
• Chen Q, Lai H. Plant-derived virus-like particles as vaccines. Hum Vaccin Immunother. 2013;9(1):26–49.
   PubMed Web of Science ®Google Scholar
• Choi HJ, Song JM, Bondy BJ, et al. Effect of osmotic pressure on the stability of whole inactivated influenza vaccine for coating on microneedles. PLoS One. 2015;10(7):1–22.
   Web of Science ®Google Scholar
• Jutras PV, D’Aoust MA, Couture MM, et al. Modulating secretory pathway pH by proton channel co-expression can increase recombinant protein stability in plants. Biotechnol J. 2015;10(9):1478–1486.
   PubMed Web of Science ®Google Scholar
• Tretyakova I, Hidajat R, Hamilton G, et al. Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein. Virology. 2016;487:163–171.
   PubMed Web of Science ®Google Scholar
• Kapczynski DR, Tumpey TM, Hidajat R, et al. Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses. Vaccine. 2016;34(13):1–7.
   Web of Science ®Google Scholar
• Quan FS, Steinhauer D, Huang C, et al. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine. 2008;26(26):3352–3361.
   PubMed Web of Science ®Google Scholar
• Quan F-S, Huang C, Compans RW, et al. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007;81(7):3514–3524.
   PubMed Web of Science ®Google Scholar
• Lee DH, Park JK, Lee YN, et al. H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals. Vaccine. 2011;29(23):4003–4007.
   PubMed Web of Science ®Google Scholar
• Neumann G, Watanabe T, Kawaoka Y. Plasmid-driven formation of influenza virus-like particles. J Virol. 2000;74(1):547–551.
   PubMed Web of Science ®Google Scholar
• Carinhas N, Bernal V, Yokomizo AY, et al. Baculovirus production for gene therapy: the role of cell density, multiplicity of infection and medium exchange. Appl Microbiol Biotechnol. 2009;81(6):1041–1049.
   PubMed Web of Science ®Google Scholar
• Petiot E, Cuperlovic-Culf M, Shen CF, et al. Influence of HEK293 metabolism on the production of viral vectors and vaccine. Vaccine. 2015; 33(44):5974–5981.
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Daniluk S, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 2007;25(19):3871–3878.
   PubMed Web of Science ®Google Scholar
• Monteiro F, Bernal V, Chaillet M, et al. Targeted supplementation design for improved production and quality of enveloped viral particles in insect-cell baculovirus expression system. J Biotechnol. 2016;233:34–41.
   PubMed Web of Science ®Google Scholar
• Roldão A, Mellado MCM, Castilho LR, et al. Virus-like particles in vaccine development. Expert Rev Vaccines. 2010;9(10):1149–1176.
   PubMed Web of Science ®Google Scholar
• Venereo-Sanchez A, Simoneau M, Lanthier S, et al. Process intensification for high yield production of influenza H1N1 Gag virus-like particles using an inducible HEK-293 stable cell line. Vaccine. 2017;35(33):4220–4228.
   Web of Science ®Google Scholar
• Robinson JM. An alternative to the scale-up and distribution of pandemic influenza vaccine. BioPharm Int Suppl. 2009;1.
   Google Scholar
• Hahn T, Courbron D, Hamer M, et al. Rapid manufacture and release of a GMP batch of avian influenza A(H7N9) virus-like particle vaccine made using recombinant baculovirus-Sf9 insect cell culture technology. Bioprocess J. 2013;12(2):4–17.
   Google Scholar
• Wirz H, Sauer-Budge AF, Briggs J, et al. Automated production of plant-based vaccines and pharmaceuticals. J Lab Autom. 2012;17(6):449–457.
   PubMedGoogle Scholar
• Landry N, Barbeau B, Charland N, et al. Plants As an innovative and accelerated vaccine-manufacturing solution. BioPharm Int Suppl. 2011;4.
   Google Scholar
• Council of Europe. Influenza vaccine (split virion, inactivated). Eur Pharmacopoeia. 2008. 867–868.
   Google Scholar
• Council of Europe. Influenza vaccine (Surface antigen, inactivated, prepared in cell cultures). Eur Pharmacopoeia. 2009. 865–867.
   Google Scholar
• Thompson CMCM, Petiot E, Lennaertz A, et al. Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches. Virol J. 2013;10(141):1–14.
   PubMedGoogle Scholar
• Zhao Q, Li S, Yu H, et al. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol. 2013;31(11):654–663.
   PubMed Web of Science ®Google Scholar
• Vicente T, Mota JPB, Peixoto C, et al. Rational design and optimization of downstream processes of virus particles for biopharmaceutical applications: current advances. Biotechnol Adv. 2011;29(6):869–878.
   PubMed Web of Science ®Google Scholar
• Effio CL, Hubbuch J. Next generation vaccines and vectors: designing downstream processes for recombinant protein-based virus-like particles. Biotechnol J. 2015;10(5):715–727.
   PubMed Web of Science ®Google Scholar
• Kissmann J, Joshi SB, Haynes JR, et al. H1N1 influenza virus-like particles : physical degradation pathways and identification of stabilizers. J Pharm Sci. 2011;100(2):634–645.
   Google Scholar
• Kalbfuss B, Genzel Y, Wolff M, et al. Harvesting and concentration of human influenza A virus produced in serum-free mammalian cell culture for the production of vaccines. Biotechnol Bioeng. 2007;97(1):73–85.
   PubMed Web of Science ®Google Scholar
• Smith GE, Pushko P Avian Influenza Chimeric VLPs. WO 2009/012489 A1 (2009).
   Google Scholar
• Wolff MW, Reichl U. Downstream processing of cell culture-derived virus particles. Expert Rev Vaccines. 2011;10(10):1451–1475.
   PubMed Web of Science ®Google Scholar
• Sugita Y, Noda T, Sagara H, et al. Ultracentrifugation deforms unfixed influenza A virions. J Gen Virol. 2011;92(11):2485–2493.
   PubMedGoogle Scholar
• Steppert P, Burgstaller D, Klausberger M, et al. Purification of HIV-1 gag virus-like particles and separation of other extracellular particles. J Chromatogr A. 2016;1455:93–101.
   PubMed Web of Science ®Google Scholar
• Cantin R, Diou J, Bélanger D, et al. Discrimination between exosomes and HIV-1: purification of both vesicles from cell-free supernatants. J Immunol Methods. 2008;338(1–2):21–30.
   PubMed Web of Science ®Google Scholar
• Nayak DP, Lehmann S, Reichl U. Downstream processing of MDCK cell-derived equine influenza virus. J Chromatogr B Anal Technol Biomed Life Sci. 2005;823(2):75–81.
   PubMed Web of Science ®Google Scholar
• Lin SY, Chiu HY, Chiang BL, et al. Development of EV71 virus-like particle purification processes. Vaccine. 2015;33(44):5966–5973.
   PubMed Web of Science ®Google Scholar
• Negrete A, Pai A, Shiloach J. Use of hollow fiber tangential flow filtration for the recovery and concentration of HIV virus-like particles produced in insect cells. J Virol Methods. 2014;195:240–246.
   PubMed Web of Science ®Google Scholar
• Lee D-H, Bae S-W, Park J-K, et al. Virus-like particle vaccine protects against H3N2 canine influenza virus in dog. Vaccine. 2013;31(32):3268–3273.
   PubMed Web of Science ®Google Scholar
• Song J-M, Choi C-W, Kwon S-O, et al. Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity. J Proteome Res. 2012;10(8):3450–3459.
   Web of Science ®Google Scholar
• Bright RA, Carter DM, Crevar CJ, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One. 2008;3(1):e1501.
   PubMed Web of Science ®Google Scholar
• Hammonds J, Chen X, Zhang X, et al. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines. Vaccine. 2007;25(47):8036–8048.
   PubMed Web of Science ®Google Scholar
• Vicente T, Burri S, Wellnitz S, et al. Fully aseptic single-use cross flow filtration system for clarification and concentration of cytomegalovirus-like particles. Eng Life Sci. 2014;14(3):318–326.
   Web of Science ®Google Scholar
• Park YC, Song JM. Preparation and immunogenicity of influenza virus-like particles using nitrocellulose membrane filtration. Clin Exp Vaccine Res. 2017;6(1):61–66.
   PubMed Web of Science ®Google Scholar
• Park JK, Lee DH, Youn HN, et al. Protective efficacy of crude virus-like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy. Influenza Other Respir Viruses. 2013;7(3):340–348.
   PubMed Web of Science ®Google Scholar
• Rajamanickam V, Herwig C, Spadiut O. Monoliths in bioprocess technology. Chromatography. 2015;2(2):195–212.
   Google Scholar
• Orr V, Zhong L, Moo-Young M, et al. Recent advances in bioprocessing application of membrane chromatography. Biotechnol Adv. 2013;31(4):450–465.
   PubMed Web of Science ®Google Scholar
• Banjac M, Roethl E, Gelhart F, et al. Purification of Vero cell derived live replication deficient influenza A and B virus by ion exchange monolith chromatography. Vaccine. 2014;32(21):2487–2492.
   PubMed Web of Science ®Google Scholar
• Ladd Effio C, Hahn T, Seiler J, et al. Modeling and simulation of anion-exchange membrane chromatography for purification of Sf9 insect cell-derived virus-like particles. J Chromatogr A. 2016;1429:142–154.
   PubMed Web of Science ®Google Scholar
• Removal of DNA and baculovirus from influenza virus-like particles using Capto TM Q. GE Healthcare Life Sciences. Application note : 28-9924-41 AA.
   Google Scholar
• Steppert P, Burgstaller D, Klausberger M, et al. Purification of HIV-1 gag virus-like particles and separation of other extra cellular particles. J Chromatogr A. 2016;1–9.
   Google Scholar
• Steppert P, Burgstaller D, Klausberger M, et al. Separation of HIV-1 gag virus-like particles from vesicular particles impurities by hydroxyl-functionalized monoliths. J Sep Sci. 2017;40(4):979–990.
   PubMed Web of Science ®Google Scholar
• Kalbfuss B, Flockerzi D, Seidel-Morgenstern A, et al. Size-exclusion chromatography as a linear transfer system: purification of human influenza virus as an example. J Chromatogr B Anal Technol Biomed Life Sci. 2008;873(1):102–112.
   PubMed Web of Science ®Google Scholar
• Center for Biologics Evaluation and Research. Guidance for Industry. Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications.
   Google Scholar
• Hutchinson EC, Charles PD, Hester SS, et al. Conserved and host-specific features of influenza virion architecture. Nat Commun. 2014;5:4816.
   PubMed Web of Science ®Google Scholar
• Le Mauff F, Mercier G, Chan P, et al. Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants. Plant Biotechnol J. 2015;13(5):717–725.
   PubMed Web of Science ®Google Scholar
• Sadowski T, Li J, Sarathi B, et al. Stability testing programs for a novel virus-like particle vaccine. BioPharm Int Suppl. 2010;23(Suppl.,):26–34.
   Google Scholar
• Kumru OS, Joshi SB, Smith DE, et al. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. Biologicals. 2014;42(5):237–259.
   PubMed Web of Science ®Google Scholar
• Quan F-S, Ko E-J, Kwon Y-M, et al. Mucosal adjuvants for influenza virus-like particle vaccine. Viral Immunol. 2013;26(6):385–395.
   PubMed Web of Science ®Google Scholar
• Allen JD, Owino SO, Carter DM, et al. Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines. Vaccine. 2017;35(38):5209–5216.
   PubMed Web of Science ®Google Scholar
• Ren Z, Ji X, Meng L, et al. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus. Virus Res. 2015;200(C):9–18.
   PubMedGoogle Scholar
• Jack Hu C-M, Chien C-Y, Liu M-T, et al. Multi-antigen avian influenza a (H7N9) virus-like particles: particulate characterizations and immunogenicity evaluation in murine and avian models. BMC Biotechnol. 2017;1:1–12.
   PubMed Web of Science ®Google Scholar
• Smith GE, Flyer DC, Raghunandan R, et al. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine. 2013;31(40):4305–4313.
   PubMed Web of Science ®Google Scholar
• Rajão DS, Pérez DR. Universal vaccines and vaccine platforms to protect against influenza viruses in humans and agriculture. Front Microbiol. 2018;9:1–21.
   PubMed Web of Science ®Google Scholar
• Sautto GA, Kirchenbaum GA, Ross TM. Towards a universal influenza vaccine: different approaches for one goal. Virol J. 2018;15(1):1–12.
   PubMedGoogle Scholar
• Galarza JM, Latham T, Cupo A. Virus-Like Particle Vaccine Conferred Complete Protection Against a Lethal Influenza Virus Challenge. Viral Immunol. 2005;18(2):365–372.
   Google Scholar
• Matassov D, Cupo A, Galarza JM. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol. 2007;20(3):441–452.
   PubMed Web of Science ®Google Scholar
• Pan Y-S, Wei H-J, Chang -C-C, et al. Construction and characterization of insect cell-derived influenza VLP: cell binding, fusion, and EGFP incorporation. J Biomed Biotechnol. 2010;506363:2010.
   Google Scholar
• Wei H-J, Chang W, Lin S-C, et al. Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. Vaccine. 2011;29(41):7163–7172.
   PubMed Web of Science ®Google Scholar
• Tao P, Luo M, Zhu D, et al. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Viral Immunol. 2009;22(4):273–281.
   PubMed Web of Science ®Google Scholar
• Prel A, Le Gall-Reculé G, Cherbonnel M, et al. Assessment of the protection afforded by triple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian influenza virus challenge in Muscovy ducks. Avian Dis. 2007;51(1 Suppl):484–489.
   PubMed Web of Science ®Google Scholar
• Pyo HM, Masic A, Woldeab N, et al. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs. Vaccine. 2012;30(7):1297–1304.
   PubMed Web of Science ®Google Scholar
• Kang S-M, Yoo D-G, Lipatov AS, et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One. 2009;4(3):e4667.
   PubMed Web of Science ®Google Scholar
• Quan F-S, Vunnava A, Compans RW, et al. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One. 2010;5(2):e9161.
   PubMed Web of Science ®Google Scholar
• Jaber Hossain M, Bourgeois M, Quan FS, et al. Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clin Vaccine Immunol. 2011;18(12):2010–2017.
   PubMedGoogle Scholar
• Wen Z, Ye L, Gao Y, et al. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res. 2009;84(3):215–224.
   PubMed Web of Science ®Google Scholar
• Schwartzman LM, Cathcart AL, Pujanauski LM, et al. An intranasal virus-like particle vaccine broadly protects mice from multiple subtypes of influenza a virus. mBio. 2015;6(4):1–9.
   Google Scholar
• Ji X, Ren Z, Xu N, et al. Intranasal immunization with influenza virus-like particles containing membrane-anchored cholera toxin B or ricin toxin B enhances adaptive immune responses and protection against an antigenically distinct virus. Viruses. 2016;8:4.
   Web of Science ®Google Scholar
• Satomi Yanase MS, Masatoshi Okamatsu CMO. Influenza virus-like particles containing HA, NA, and M1 induced protection in chickens against a lethal challenge with the highly pathogenic H5N1 avian influenza virus. J Vaccines Vaccin. 2013;4(6):1–7.
   Google Scholar
• Pushko P, Pearce MB, Ahmad A, et al. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine. 2011;29(35):5911–5918.
   PubMed Web of Science ®Google Scholar
• Haynes JR, Dokken L, Wiley JA, et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine. 2009;27(4):530–541.
   PubMed Web of Science ®Google Scholar
• Tretyakova I, Pearce MB, Florese R, et al. Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses. Virology. 2013;442(1):67–73.
   PubMed Web of Science ®Google Scholar
• Pushko P, Tretyakova I, Hidajat R, et al. Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens. Virology. 2017;501:176–182, (November 2016)
   PubMed Web of Science ®Google Scholar
• Song JM, Hossain J, Yoo DG, et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology. 2010;405(1):165–175.
   PubMed Web of Science ®Google Scholar
• Liu YV, Massare MJ, Pearce MB, et al. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets. Vaccine. 2015;33(18):2152–2158.
   PubMed Web of Science ®Google Scholar
• Pushko P, Kort T, Nathan M, et al. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine. 2010;28(30):4771–4776.
   PubMed Web of Science ®Google Scholar
• Krammer F, Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov. 2015;14(3):167–182.
   PubMed Web of Science ®Google Scholar
• Partridge J, Kieny MP. Global production capacity of seasonal influenza vaccine in 2011. Vaccine. 2013;31(5):728–731.
   PubMed Web of Science ®Google Scholar
• Pillet S, Racine T, Nfon C, et al. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets. Vaccine. 2015;33(46):6282–6289.
   PubMed Web of Science ®Google Scholar
• Landry N, Ward BJ, Trépanier S, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One. 2010;5(12):e15559.
   PubMed Web of Science ®Google Scholar
• Medicago. Press release - medicago to build $245m production facility in quebec city. (2015).
   Google Scholar
• Yusibov V, Kushnir N, Streatfield SJ. Advances and challenges in the development and production of effective plant-based influenza vaccines. Expert Rev Vaccines. 2015;14(4):519–535.
   PubMed Web of Science ®Google Scholar
• Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults. Available from: https://clinicaltrials.gov/ct2/show/NCT02307851.
   Google Scholar
• Hahn T, Courbron D, Hamer M, et al.Rapid Manufacture and Release of a GMP Batch of Avian Influenza A(H7N9) Virus-Like Particle Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology. BioProcess J. 2013;12(2): 4–17.
   Google Scholar
• Quan F, Kim M, Lee B, et al. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology. 2012;430(2):127–135.
   PubMed Web of Science ®Google Scholar
• Chang GR-L, Lai S-Y, Chang P-C, et al. Production of immunogenic one-component avian H7-subtype influenza virus-like particles. Process Biochem. 2011;46(6):1292–1298.
   Web of Science ®Google Scholar
• Rybicki EP. Plant-based vaccines against viruses. Virol J. 2014;11(1):205.
   PubMedGoogle Scholar
• Vézina L-P, Ward BJ, D’Aoust M-A, et al. Influenza virus-like particles produced in nicotiana benthamiana protect against a lethal viral challenge in Mice. In: Commercial Plant-Produced Recombinant Protein Products. Biotechnology in Agriculture and Forestry. Howard J, Hood E (Eds.). Springer Berlin Heidelberg. 2014; 83–102.
   Google Scholar